Qilu Tiancheng Biotechnology

Qilu Tiancheng Biotechnology is a specialized biotechnology subsidiary of Qilu Pharmaceutical, one of China's leading pharmaceutical enterprises. Based in Jinan, the company focuses on the research, development, and manufacturing of innovative biologics, particularly in the field of oncology. Its pipeline includes a variety of monoclonal and bispecific antibodies targeting well-established pathways such as PD-1/PD-L1 and VEGF, as well as emerging targets like Claudin 18.2. Leveraging the extensive manufacturing and commercialization infrastructure of the Qilu Pharmaceutical Group, Qilu Tiancheng is positioned to advance complex biological therapies from early-stage discovery through large-scale production.